Cancer-Associated Pain, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Conditions
Brief summary
This study compares patients' attitudes regarding marijuana products for medical use and other treatments for cancer-related pain. This study may help researchers gain better understanding of patient's perception on their use of marijuana products in treating cancer-related pain and other common cancer-related symptoms.
Detailed description
PRIMARY OBJECTIVE: I. To determine the patient's reported preference for cancer pain improvement with opioids, opioids with delta-9-tetrahydrocannabinol (THC)-marijuana and/or opioids with cannabidiol (CBD). SECONDARY OBJECTIVES: I. To determine the association between perception of cancer-related symptom relief and use of THC-marijuana and/or CBD. II. To compare patient perception of THC-marijuana and/or CBD versus (vs.) cancer treatments in treatment of cancer. III. To evaluate patient report of adverse effects experienced while using THC-marijuana and/or CBD. IV. To evaluate patient reported concerns while using THC-marijuana and/or CBD. V. To evaluate patient attitude of dosing, forms and use of THC-marijuana and/or CBD. VI. To evaluate demographic, physical and psychosocial factors that influence patient perception and attitudes of THC-marijuana and/or CBD. VII. To explore the difference of patient perception of THC-marijuana and CBD in cancer centers in a legalized vs. a non-legalized state. VIII. To explore the patient reported preference of THC-marijuana and CBD for cancer pain and symptom relief of patients in a Supportive Care Center vs. Integrative Medicine Center at University of Texas (U.T.) MD Anderson. OUTLINE: Patients' medical records are reviewed and then complete questionnaires over 27 minutes.
Interventions
OTHERElectronic Health Record Review
Medical records reviewed
OTHERQuestionnaire Administration
Complete questionnaires
Sponsors
M.D. Anderson Cancer Center
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients (inpatient or outpatient) seen by the Palliative Care and Integrative Medicine teams at The University of Texas MD Anderson Cancer Center (Texas) and the Palliative Care team at Banner MD Anderson Cancer Center (Arizona) * Patients must be primary residents of Texas or Arizona * Patients able to speak and read English * Patients are 18 years old and above * Patients should have a cancer diagnosis, cancer-associated pain, and taking strong opioids (morphine, oxycodone, hydrocodone, hydromorphone, oxymorphone, methadone, fentanyl) * Patients who have used in the past 3 months or are using alternative botanical pain management while under prescription opioids
Exclusion criteria
* Patients who are not able to speak or read English * Altered mental status as determined by the interviewer based on the ability to understand the nature of the study and consent process * Patients who have not used medical marijuana and/or CBD products * Patients who do not have cancer * Patients who do not have cancer-associated pain * Patients who are not taking opioids
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients who prefer opioids with THC-marijuana and/or opioids with cannabidiol (CBD) to opioids alone for their cancer pain relief | through study completion, an average of 1 year | Will be calculated and reported along with a 95% confidence interval. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Perception of cancer-related symptom relief | through study completion, an average of 1 year | Will be associated with use of THC-Marijuana and/or CBD. Will be evaluated by generalized linear mixed models to account for the dependency among those patients who have used/are using both. |
| Patient perception of THC-marijuana and/or CBD | through study completion, an average of 1 year | Compared to cancer treatments in treatment of cancer. Will be evaluated by generalized linear mixed models to account for the dependency among those patients who have used/are using both. |
| To evaluate patient report of adverse effects experienced while using THC-marijuana and/or CBD | through study completion, an average of 1 year | Patient reported outcomes will be summarized by frequency and proportion. |
| To evaluate patient reported concerns while using THC-marijuana and/or CBD | through study completion, an average of 1 year | Patient reported outcomes will be summarized by frequency and proportion. |
| Patient attitude of dosing, forms and use of THC-marijuana and/or CBD | through study completion, an average of 1 year | Patient reported outcomes will be summarized by frequency and proportion. |
| Demographic, physical and psychosocial factors that influence patient perception and attitudes of THC-marijuana and/or CBD | through study completion, an average of 1 year | Will be evaluated by Wilcoxon rank sum (Kruskal-Wallis) test or chi-square (Fisher's exact) test, when appropriate. To further evaluate these associations, univariate and multivariable logistic regression models will be fitted. Multiple comparisons will be adjusted where appropriate. |
| To explore the difference of patient perception of THC-marijuana and CBD in cancer centers in a legalized vs. a non-legalized state. | through study completion, an average of 1 year | Differences will be explored. |
| Patient reported preference of THC-Marijuana and CBD for cancer pain and symptom relief of patients | through study completion, an average of 1 year | Will be explored between a Supportive Care Center vs. Integrative Medicine Center at University of Texas (U.T.) MD Anderson. Will be evaluated by Wilcoxon rank sum (Kruskal-Wallis) test or chi-square (Fisher's exact) test, when appropriate. To further evaluate these associations, univariate and multivariable logistic regression models will be fitted. Multiple comparisons will be adjusted where appropriate. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORKimberson C Tanco
M.D. Anderson Cancer Center
Outcome results
None listed